Heterogeneity in breast cancer linked to risk of metastasis and treatment response
· Medical Xpressedited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add to Preferred Sources
Differences within breast tumors and between patients are associated with the risk of metastasis and response to endocrine therapy, according to a new doctoral thesis from Karolinska Institutet. The findings also highlight the importance of long-term follow-up in capturing the full benefit of treatment.
In hormone-sensitive breast cancer, the cancer cells have receptors for the hormone estrogen, which can stimulate their growth. Patients can therefore be treated with endocrine therapy, but the treatment does not benefit everyone to the same extent. Tumor cells can also remain dormant in the body and begin growing again 10 to 20 years later.
In his thesis, Oscar Danielsson at the Department of Oncology-Pathology investigated how different types of variation in hormone-sensitive breast cancer are associated with the long-term risk of metastasis and the benefit of endocrine therapy.
"Breast cancer can vary both within the tumor and from one patient to another. Our findings show that these differences may be associated with the risk of metastasis and how much patients benefit from treatment," says Danielsson.
Treatment benefit changed over time
The thesis also examined two common types of hormone-sensitive breast cancer, luminal A and luminal B. Both groups showed long-term benefit from treatment with tamoxifen. For patients with luminal B, much of the benefit was already apparent after five years. For those with luminal A, the benefit was smaller at five years but became greater with longer follow-up.
"For patients with luminal A, a study with only five years of follow-up would have missed much of the later benefit of tamoxifen. This shows why long-term follow-up is important when studying this type of breast cancer," says Danielsson.
Another part of the thesis looked at variation within individual tumors. Patients whose tumors showed greater variation in progesterone receptor levels had an approximately 40% higher rate of metastasis during follow-up than patients whose tumors showed less variation. Despite this, they still benefited from endocrine therapy.
Two of the studies in the thesis also used artificial intelligence to analyze images of tumor tissue. The analyses identified patterns associated with a higher risk of metastasis. One AI model also identified a group of patients who clearly benefited from treatment with goserelin. However, the findings need to be confirmed in other patient groups before the method can be used in clinical practice.
The thesis work was supervised by docent Linda Lindström at the Department of Oncology-Pathology, Karolinska Institutet.
Publication details
Long-term risk of metastasis and heterogeneity in estrogen receptor-positive breast cancer, openarchive.ki.se/articles/the … 238365?file=69714762
Journal information: International Journal of Cancer
Key medical concepts
MetastasisENDOCRINE THERAPYTamoxifen
Clinical categories
OncologyWomen's health Provided by Karolinska Institutet Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Heterogeneity in breast cancer linked to risk of metastasis and treatment response (2026, November 9) retrieved 9 November 2026 from https://medicalxpress.com/news/2026-11-heterogeneity-breast-cancer-linked-metastasis.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.